Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Significance The study demonstrates that V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint that is preferentially expressed at higher levels in pancreatic cancer. The study gives a detailed analysis of immune infiltration in primary and metastatic pancreatic tumors compared with melanoma, which differs in its tumor/stromal distribution. Our data indicate that human pancreatic tumors express CD68 + macrophages and highlight the inhibitory checkpoint molecule VISTA as a potential immunotherapeutic target in pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“VISTA is another inhibitory checkpoint molecule that is largely and constitutively expressed on myeloid cells and also on T cells, and NK cells (Blando et al., 2019; Gao et al., 2017; Wang et al., 2019a).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Blando et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“targeting the PD-1–PD-L1 axis has not been successful in pancreatic cancer (3, 4, 8).”
BackgroundResultWHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Self-citationMcGuire, S. (2016) · Advances in Nutrition · doi:10.3945/an.116.012211 · Cited by 1,898
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,257 · cited 2×
“targeting the PD-1–PD-L1 axis has not been successful in pancreatic cancer (3, 4, 8).”
BackgroundResultDynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990
A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma
Clark, W. H., Elder, D. E., Guerry, D., Epstein, M. N., Greene, M. H., & Van Horn, M. (1984) · Human Pathology · doi:10.1016/s0046-8177(84)80310-x · Cited by 975
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 872
Metabolic Interactions in the Tumor Microenvironment
Lyssiotis, C. A., & Kimmelman, A. C. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.003 · Cited by 853
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710 · cited 2×
“VISTA is predominantly expressed on myeloid cells (35).”
BackgroundGao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594 · cited 1×
“Our group previously reported that anti−CTLA-4 therapy can increase VISTA expression on CD68 macrophages, which have an M2 phenotype, as a resistance mechanism in prostate tumors and represents an immune checkpoint target (36).”
BackgroundSelf-citationTsujikawa, T., Kumar, S., Borkar, R. N., Azimi, V., Thibault, G., Chang, Y. H., Balter, A., Kawashima, R., Choe, G., Sauer, D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.037 · Cited by 568 · cited 1×
“A recent study demonstrated that a higher degree of myeloid cell infiltration is correlated with poor clinical responses in patients with pancreatic cancer who received GVAX vaccination, an allogeneic, GM-CSF-secreting cellular immunotherapy (11).”
BackgroundLe, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L., Diaz, L. A., Donehower, R. C., Jaffee, E. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829fb7a2 · Cited by 564
Fukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., Kato, K., Kurokawa, T., Suzuoki, M., Nakakubo, Y., et al. (2004) · Pancreas · doi:10.1097/00006676-200401000-00023 · Cited by 532
VISTA Regulates the Development of Protective Antitumor Immunity
Le Mercier, I., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P., Noelle, R. J., & Wang, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1506 · Cited by 486 · cited 1×
“Preclinical data have established that VISTA can suppress T-cell activation and hinders the development of tumor-specific immunity, but data on the functionality of VISTA cells in human cancer are lacking (35, 38).”
BackgroundWinograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459 · cited 2×
“targeting the PD-1–PD-L1 axis has not been successful in pancreatic cancer (3, 4, 8).”
BackgroundResultThe biologic forms of malignant melanoma
Clark, W. H., Elder, D. E., & Van Horn, M. (1986) · Human Pathology · doi:10.1016/s0046-8177(86)80032-6 · Cited by 274
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
Lines, J. L., Sempere, L. F., Broughton, T., Wang, L., & Noelle, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0072 · Cited by 236
Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
Balli, D., Rech, A. J., Stanger, B. Z., & Vonderheide, R. H. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2128 · Cited by 235 · cited 1×
“Recently, another group reported that pancreatic tumors with high cytolytic activity have increased expression of multiple immune checkpoint genes such as CTLA4, TIGIT, TIM3, and VISTA (39).”
BackgroundCurrent progress in immunotherapy for pancreatic cancer
Foley, K., Kim, V., Jaffee, E., & Zheng, L. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.020 · Cited by 203
Inflammatory networks and immune surveillance of pancreatic carcinoma
Vonderheide, R. H., & Bayne, L. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.006 · Cited by 200
Clark, C. E., Beatty, G. L., & Vonderheide, R. H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.037 · Cited by 181
Mihm, M. C., Clark, W. H., & From, L. (1971) · New England Journal of Medicine · doi:10.1056/nejm197105132841907 · Cited by 162
Salmon, J. K., Armstrong, C. A., & Ansel, J. C. (1994) · PubMed Central · Cited by 136
Shibuya, K. C., Goel, V. K., Xiong, W., Sham, J. G., Pollack, S. M., Leahy, A. M., Whiting, S. H., Yeh, M. M., Yee, C., Riddell, S. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096565 · Cited by 119
Self-citationImmune infiltrates as predictive markers of survival in pancreatic cancer patients
Protti, M. P., & De Monte, L. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00210 · Cited by 91
Helm, O., Mennrich, R., Petrick, D., Goebel, L., Freitag‐Wolf, S., Röder, C., Kalthoff, H., Röcken, C., Sipos, B., Kabelitz, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094357 · Cited by 82
Histology of the exocrine pancreas
Motta, P. M., Macchiarelli, G., Nottola, S. A., & CORRER, S. (1997) · Microscopy Research and Technique · doi:10.1002/(sici)1097-0029(19970601)37:5/6<456::aid-jemt9>3.0.co;2-b · Cited by 81
Scoazec, J., & Couvelard, A. (2017) · Annales de Pathologie · doi:10.1016/j.annpat.2017.10.003 · Cited by 78 · cited 1×
“Scoazec JY, Couvelard A, Reseau T; Réseau TENpath (2017) [Classification of pancreatic neuroendocrine tumours: Changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future].”
BackgroundLentigo maligna and malignant melanoma in situ, lentigo maligna type
Flotte, T. J., & Mihm, M. C. (1999) · Human Pathology · doi:10.1016/s0046-8177(99)90197-1 · Cited by 69
A unifying concept of malignant melanoma: Biologic aspects
Ackerman, A. B., & David, K. M. (1986) · Human Pathology · doi:10.1016/s0046-8177(86)80030-2 · Cited by 65
Ait-Belkacem, R., Bol, V., Hamm, G. R., Schramme, F., den Eynde, B. J. V., Poncelet, L., Pamelard, F., Stauber, J., & Gomes, B. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217712659 · Cited by 35
Saida, T., Kawachi, S., Takata, M., Kurita, H., Kurashina, K., Kageshita, T., Tonogi, M., Okazaki, Y., Yamane, G., Takubo, K., et al. (2004) · Pathology · doi:10.1080/00313020412331282753 · Cited by 29
T-cell immunotherapy of cancer
Melief, C. J. M., & Kast, W. M. (1991) · Research in Immunology · doi:10.1016/0923-2494(91)90042-h · Cited by 27
Pancreatic Pathology: A Practical Review
Bellizzi, A. M., & Frankel, W. L. (2009) · Laboratory Medicine · doi:10.1309/lm5my3ocdwwks6nm · Cited by 14
Cited by
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Self-citationNovel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
“, VISTA was regard as a promising target for patients with pancreatic cancer [120] and the HMBD-002, a novel antiVISTA antibody developed by Hummingbird Bioscience, have received a financial assistance from Cancer Prevention and Research Institute of Texas (CPRIT) with the plan to initiate clinical trials in 2020.”
BackgroundChallenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Bockorny, B., Semenisty, V., Macarulla, T., Borazanci, E., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 557
Metadata
- Authors
- Blando, J., Sharma, A., Higa, M. G., Zhao, H., Vence, L., Yadav, S. S., Kim, J., Sepulveda, A. M., Sharp, M., Maitra, A., Wargo, J., Tetzlaff, M., Broaddus, R., Katz, M. H. G., Varadhachary, G. R., Overman, M., Wang, H., Yee, C., Bernatchez, C., Iacobuzio-Donahue, C., Basu, S., Allison, J. P., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Janssen Oncology Therapeutic Area, Janssen Research and Development, LLC, Pharmaceutical Companies of Johnson & Johnson, Spring House, PA 19477;
- David Rubenstein Pancreatic Cancer Research Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065;
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2019-01-11
- Volume
- 116
- Issue
- 5
- Pages
- 1692-1697
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6358697
- OpenAlex
- W2910310961
- Cited by
- 334
- References
- 42
- Citations by year
- 2026: 24 · 2025: 31 · 2024: 46 · 2023: 45 · 2022: 50 · 2021: 56 · 2020: 56 · 2019: 26
- FWCI
- 19.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (CA1633793)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- VISTA, immune checkpoint, pancreatic cancer, melanoma, tumor immune infiltrate, CD68+ macrophages, tumor stroma, metastatic pancreatic tumor, immunotherapy targets
- MeSH terms
- Adenocarcinoma, Humans, Immunotherapy, Lymphocyte Activation, Melanoma, Pancreatic Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Carcinoma, Pancreatic Ductal, Tumor Microenvironment, B7 Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.